Breaking News

Australia and New Zealand Prothrombin Complex Concentrate Projection By COVID-19 Impact on Industry Size, Share, Movements by Trend Analysis, Growth Status, Revenue Analysis to 2028

Market Overview

The global Australia and New Zealand Prothrombin Complex Concentrate market size is expected to reach USD 71.95 billion by 2027, exhibiting a CAGR of 7.9% during the forecast period. The growing awareness regarding the prominence of dietary supplements, probiotics, and functional will have a tremendous impact on the the market, states Fortune Business Insights, in a report, titled “Australia and New Zealand Prothrombin Complex Concentrate Market Size, Share & Industry Analysis, By Ingredient Type (Probiotics, Prebiotics, Digestive Enzymes/Food Enzymes, and Others), By Product Type (Functional Foods & Beverages, Vitamins & Dietary Supplements, and Others), By End User (Supermarkets/Hypermarkets, Hospital Pharmacies, Online Pharmacies, and Others), and Region, 2020-2027.” The market size stood at USD 37.93 billion in 2019.

Request for Sample Report PDF @

The coronavirus incident has caused massive loss and disruption to various industries across the globe. We understand that this health disaster has negatively impacted various sectors across the globe. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic.

We are making endless efforts to uplift businesses in this crucial need of the hour. Our expertise and experience can offer enormous benefits to help regain during this global pandemic.

The report on the market incorporates:

  • Wide-ranging inspection of the industry
  • Significant information about segments
  • Leading regions in the market
  • Competitive landscape
  • Recent developments and drivers
  • COVID-19 impact

Market Driver:

Heavy R&D Investments by Industry Players to Incite Development

The growing concerns regarding gut health among consumers have impelled manufacturers to invest heavily in research and development of Australia and New Zealand Prothrombin Complex Concentrate products. According to a large-scale multinational research study conducted in 2020, more than 40% of the people worldwide have functional gastrointestinal disorders, affecting the quality of life and healthcare use. Thus, the surging demand for natural and safe products will create opportunities for the Australia and New Zealand Prothrombin Complex Concentrate industry.  Furthermore, the development of innovative products by key players can have an exceptional effect on the market. For instance, in November 2020, Beroni Group, an Australia-based diversified biopharmaceutical enterprise, announced a new product Beilemei in China. It is a probiotic health product aimed at modulating the balance of human intestinal flora.

COVID-19 Impact:

Surging Demand for Health Products to Boost Business Amid COVID-19

The market has faced limitations due to the disruption caused by COVID-19 in the logistics and supply chain. However, the demand for functional products has remained steady throughout the epidemic. The prominent companies operating in the market focus on their distribution network and production lines to cater to consumers’ demands. According to Yakult U.S.A. Inc.’s annual report, in their overseas food and beverage business, average daily sales rose by 1.6% from the prior year to 31,624 bottles in 2020. Moreover, the growing cognizance about dietary supplements and healthy products will subsequently uplift the Australia and New Zealand Prothrombin Complex Concentrate market growth during the coronavirus pandemic. According to the Food & Beverage and Supplements Report 2020, almost one-third of consumers consume more supplements (31%), functional foods, or beverages (29%).

Regional Analysis:

Adoption of Organic Products to Propel Market in Europe

North America is expected to hold the largest Australia and New Zealand Prothrombin Complex Concentrate market share during the forecast period. The growth is attributed to the rising geriatric population in the US and Canada. The surging number of gastrointestinal issues coupled with the presence of a large number of manufacturers in the region. Europe is expected to expand exponentially due to the rising adoption of natural and safe Australia and New Zealand Prothrombin Complex Concentrate products. The Middle East & Africa is expected to proliferate owing to the increasing consumer spending.

Key Development:

April 2018: Sundyota Numandis, a major leader in clinically proven and safe healthcare solutions, announced its partnership with an Italian firm to launch the world’s most researched probiotic product, Lactobacillus rhamnosus GG, in the Indian market.

Ask for Customization @

The Report Lists the Key Players in the Market:


  • Yakult Honsha Co., Ltd. (Tokyo, Japan)
  • Cie Gervais Danone (Paris, France)
  • Sanofi (Paris, France)
  • BASF SE (Ludwigshafen, Germany)
  • Bayer AG (Leverkusen, Germany)
  • Chr. Hansen Holding A/S (Hørsholm, Denmark)
  • Nestle S.A. (Vevey, Switzerland)
  • Deerland Probiotics & Enzymes, Inc (United States)
  • DuPont (Delaware, United States)
  • Other Prominent Players


Table Of Content:

  1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

  1. Key Insights

4.1 Epidemiology of Coagulation Factor Deficiency in Australia and New Zealand

4.2 Recent Industry Developments – Partnerships, Mergers & Acquisitions

4.3 Regulatory Scenario – For Key Countries

4.4 Analysis in Relation to Alternatives to PCC

4.5 PCC Market: Reimbursement Scenario & Key Industry Trends

4.6 Impact of COVID-19 on PCC Market

  1. Australia & New Zealand Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Product – By Value (US$, Mn)

5.2.1 3-factor PCC

5.2.2 4-factor PCC

5.3. Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)

5.3.1 Acquired Coagulation Factor Deficiency

5.3.2 Congenital Coagulation Factor Deficiency

5.4 Market Analysis, Insights and Forecast – By End User – By Value (US$, Mn)

5.4.1 Hospitals

5.4.2 Ambulatory Surgical Centers

5.4.3 Others

  1. Competitive Analysis

6.1. Key Industry Developments

6.2. Global Market Share Analysis (2019)

6.3. Competition Dashboard

6.4. Comparative Analysis – Major Players

6.5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (based on availability))

6.5.1 CSL Limited

6.5.2 Grifols SA

6.5.3 Octapharma AG

6.5.4 Sanquin

6.5.5 Kedrion S.p.A

6.5.6 Shire (Takeda Pharmaceutical Company Limited)

6.5.7 Other Players

  1. Strategic Recommendations


Continued. . .

Related Article @

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]




Leave a Reply

Your email address will not be published. Required fields are marked *